Enteral lipid supplementation in severe retinopathy of prematurity

Takeaway

  • Enteral arachidonic acid (AA) and docosahexaenoic acid (DHA) supplementation lowers the risk of severe retinopathy of prematurity (ROP) by 50% and produces higher overall serum levels of both AA and DHA compared with standard care in extremely preterm infants.

Why this matters

  • Extremely preterm infants miss the third-trimester transfer of maternal polyunsaturated fatty acids AA and DHA, leading to deficiencies which contribute to multiple morbidities including ROP (neurovascular disease that can cause blindness).

  • Enteral AA and DHA supplementation may constitute a more physiological and faster-acting option versus standard care for reducing ROP risk in very preterm infants; however, further trials are required for validation and to identify optimal fatty acid composition for this group.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.